SCI-210 is intended for the treatment of children with autism spectrum disorder. Credit: Ground Picture / Shutterstock.

SciSparc has announced plans to initiate a clinical trial evaluating SCI-210 in children with autism spectrum disorder (ASD) in Israel.

The move comes following approvals from the Israeli Medical Cannabis Agency (IMCA) at the Israeli Ministry of Health and the Soroka University Medical Center Ethics Committee.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The placebo-controlled, randomised, double-blind trial will compare the tolerability, efficacy, and safety of SCI-210 against CBD alone in children with ASD.

Its design includes a cross-over, double-blind, placebo-controlled, randomised study of 60 children with ASD, assessed for 20 weeks.

The Clinical Global Impressions-Improvement (CGI-I) performed by a clinician, the Aberrant Behavior Checklist-Community parent questionnaire, and the effective therapeutic dose are the primary efficacy endpoints of the study.

See Also:

SciSparc CEO Oz Adler said: “The initiation of this clinical trial represents a significant step forward for our proprietary SCI-210 as we work to develop a novel treatment for children and adolescents with ASD.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Given there are very few safe and effective treatments for reducing ASD symptoms, we believe that SCI-210 potentially introduces a safe and effective solution to this condition, which represents a clear unmet medical need.

“We hope the outcome of the trial will enable the company to proceed with the commercialisation process for SCI-210 in Israel.”

SciSparc intends to further commercialise SCI-210 globally in various regions, upon receiving respective regulatory approvals.

The study design was planned in consultation with the National Autism Research Center in Israel.

The company is also engaged in developing various therapeutics for treating pain, Alzheimer’s disease and agitation, ASD, status epilepticus, and Tourette Syndrome.